Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| IO Biotech, Inc. | 7,901,234 | reported | 09 Aug 2023 | tx 7+21,851,920−370,129 |
| scPharmaceuticals Inc. | 3,183,986 | reported | 21 Nov 2017 | tx 5+3,183,986−18,160,328 |
| Lexeo Therapeutics, Inc. | 1,608,687 | reported | 07 Nov 2023 | tx 5+1,835,959−16,615,532 |
| Trevi Therapeutics, Inc. | 1,151,544 | reported | 09 May 2019 | tx 3+1,151,544−6,849,315 |
| Enliven Therapeutics, Inc. | 0 | reported | 16 Mar 2020 | tx 5+1,432,722−7,843,685 |
| Celladon Corp | 0 | reported | 04 Feb 2014 | tx 7+1,774,349−19,666,185 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 07 Nov 2023 | CONVERSION | Lexeo Therapeutics, Inc. | 287,213 | — | |
| 07 Nov 2023 | CONVERSION | Lexeo Therapeutics, Inc. | 1,321,474 | — | |
| 07 Nov 2023 | PURCHASE | Lexeo Therapeutics, Inc. | 227,272 | 11.00 USD | first after silence |
| 07 Nov 2023 | CONVERSION | Lexeo Therapeutics, Inc. | 2,615,533 | — | deriv |
| 07 Nov 2023 | CONVERSION | Lexeo Therapeutics, Inc. | 13,999,999 | — | deriv |
| 09 Aug 2023 | GRANT_AWARD | IO Biotech, Inc. | 7,901,234 | 1.90 USD | |
| 09 Aug 2023 | GRANT_AWARD | IO Biotech, Inc. | 7,901,234 | 0.13 USD | deriv |
| 09 Nov 2021 | CONVERSION | IO Biotech, Inc. | 2,014,161 | — | |
| 09 Nov 2021 | CONVERSION | IO Biotech, Inc. | 1,892,434 | — | |
| 09 Nov 2021 | PURCHASE | IO Biotech, Inc. | 2,142,857 | 14.00 USD | first after silence |
| 09 Nov 2021 | CONVERSION | IO Biotech, Inc. | 219,595 | 0.00 USD | deriv |
| 09 Nov 2021 | CONVERSION | IO Biotech, Inc. | 150,534 | 0.00 USD | deriv |
| 16 Mar 2020 | PURCHASE | Enliven Therapeutics, Inc. | 187,500 | 16.00 USD | |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 1,245,222 | — | |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 5,470,492 | 0.00 USD | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 1,894,444 | 0.00 USD | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 478,749 | 0.00 USD | deriv |
| 09 May 2019 | PURCHASE | Trevi Therapeutics, Inc. | 375,000 | 10.00 USD | first after silence |
| 09 May 2019 | CONVERSION | Trevi Therapeutics, Inc. | 776,544 | — | |
| 09 May 2019 | CONVERSION | Trevi Therapeutics, Inc. | 6,849,315 | 0.00 USD | deriv |
| 21 Nov 2017 | PURCHASE | scPharmaceuticals Inc. | 654,762 | 14.00 USD | first after silence |
| 21 Nov 2017 | CONVERSION | scPharmaceuticals Inc. | 1,544,858 | — | |
| 21 Nov 2017 | CONVERSION | scPharmaceuticals Inc. | 984,366 | — | |
| 21 Nov 2017 | CONVERSION | scPharmaceuticals Inc. | 7,067,945 | 0.00 USD | deriv |
| 21 Nov 2017 | CONVERSION | scPharmaceuticals Inc. | 11,092,383 | 0.00 USD | deriv |
4 purchases reported after at least 12 months of silence — most recent on 07 Nov 2023.